INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion in Q3 2025, maintaining robust year-on-year growth of approximately 40%, driven by dual growth engines in oncology and comprehensive pipelines.

To date, INNOVENT BIO has secured approvals for 16 products, with 2 candidates under review by China's NMPA and 4 novel drug molecules in Phase 3 or pivotal clinical studies. Additionally, around 15 new drug candidates have entered clinical trials.

2025 marks a pivotal year for the company as it transitions into a new phase of dual-engine growth and global innovation, steadily advancing toward its vision of becoming a world-class biopharmaceutical company.